ArticleDrug and alcohol dependence2026
Comparison of persons who died of drug overdoses with and without evidence of hepatitis C, United States, 2019-2024.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInjection drug use is the most common risk factor for hepatitis C virus (HCV) infection. Despite decreases in injection drug use among overdose decedents during 2020-2022, reported cases of newly-acquired hepatitis C remained relatively stable. This analysis compares sociodemographic characteristics and circumstances among overdose decedents with and without evidence of hepatitis C to inform prevention.
methodsCDC's State Unintentional Drug Overdose Reporting System (SUDORS) collects data on unintentional and undetermined intent drug overdose deaths, including HCV infection information. Percentages of overdose deaths during July 2019-December 2024 with sociodemographic characteristics, drugs involved, and circumstances were calculated by hepatitis C evidence (48 jurisdictions). To assess trends, the percentage of overdose deaths with hepatitis C evidence was calculated by 6-month period from July 2019 to December 2024 (30 consistently reporting jurisdictions).
resultsAmong 328,754 decedents, compared to those without hepatitis C evidence (94.6%), those with hepatitis C evidence (5.4%) more often were aged ≥ 55 years (36.0% vs. 24.7%) and non-Hispanic White (75.9% vs. 63.9%), and had ≥ 1 recent touchpoint or potential intervention opportunity (e.g., mental health treatment, nonfatal overdose; 40.3% vs. 23.9%). The percentage with hepatitis C evidence increased from 5.3% during July-December 2019 to 7.2% during July-December 2024.
conclusionsImplementing community-based services to prevent infectious disease spread and overdose, accessible hepatitis C testing, linkage to substance use disorder treatment and curative hepatitis C treatment, and robust public health surveillance to identify populations for tailored prevention efforts might help address hepatitis C and drug use epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.